In Vitro Diagnostics
This article was originally published in SRA
US FDA releases guidance on allowing waivers under CLIA
You may also be interested in...
Despite a recent disappointment in a similar partnership with BioNTech, Genentech is pushing ahead with its neoantigen-targeting strategy.
Dr Reddy’s Laboratories has launched a generic version of Sensipar in the US, the former blockbuster to treat hyperparathyroidism, with originator Amgen having previously been involved in multiple intellectual property fights over agreements with ANDA sponsors Teva and Cipla.
The American Telemedicine Association backed use of more telehealth providers and changes to remote monitoring reimbursements in comments to the US Medicare agency.